Evidence map›Paper›PMID 38956428›Full record

ArticleCell death & disease2024

Correction: PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target.

Shaifali Singh, Nai Yang Yeat, Ya-Ting Wang, Shu-Yu Lin, I-Ying Kuo, Kuen-Phon Wu, Won-Jing Wang, Wen-Ching Wang, Wu-Chou Su, Yi-Ching Wang and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Shaifali Singh *Institute of Biological Chemistry, Academia Sinica, Taipei, 115, Taiwan.
Nai Yang Yeat *Institute of Biological Chemistry, Academia Sinica, Taipei, 115, Taiwan.
Ya-Ting WangInstitute of Biological Chemistry, Academia Sinica, Taipei, 115, Taiwan.
Shu-Yu LinInstitute of Biological Chemistry, Academia Sinica, Taipei, 115, Taiwan.
I-Ying KuoDepartment of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan.
Kuen-Phon WuInstitute of Biological Chemistry, Academia Sinica, Taipei, 115, Taiwan.ORCID http://orcid.org/0000-0002-1525-6004
Won-Jing WangInstitute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.ORCID http://orcid.org/0000-0001-9733-0839
Wen-Ching WangInstitute of Molecular & Cellular Biology and Department of Life Science, National Tsing Hua University, Hsinchu, 300, Taiwan.
Wu-Chou SuDivision of Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan.
Yi-Ching WangDepartment of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan.ORCID http://orcid.org/0000-0002-7694-2067
Ruey-Hwa ChenInstitute of Biological Chemistry, Academia Sinica, Taipei, 115, Taiwan. rhchen@gate.sinica.edu.tw.ORCID http://orcid.org/0000-0001-8124-5832

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38956428
PMCPMC11219715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.